A carregar...
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels correlated with measures of disease burden were no...
Na minha lista:
| Publicado no: | Front Neurol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7477386/ https://ncbi.nlm.nih.gov/pubmed/32982936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00921 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|